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Oxidative stress is a possible pathogenesis of hyperalgesia. Advanced oxidation protein products (AOPPs),
a new family of oxidized protein compounds, have been considered as a novel marker of oxidative stress.
However, the role of AOPPs in the mechanism of hyperalgesia remains unknown. Our study aims to
investigate whether AOPPs have an effect on hyperalgesia and the possible underlying mechanisms. To
identify the AOPPs involved, we induced hyperalgesia in rats by injecting complete Freund’s adjuvant
(CFA) in hindpaw. The level of plasma AOPPs in CFA-induced rats was 1.6-fold in comparison with what
in normal rats (Po0.05). After intravenous injection of AOPPs-modiﬁed rat serum albumin (AOPPs-RSA)
in Sprague-Dawley rats, the paw mechanical thresholds, measured by the electronic von Frey system,
signiﬁcantly declined. Immunoﬂuorescence staining indicated that AOPPs increased expressions of
NADPH oxidase 1 (Nox1), NADPH oxidase 4 (Nox4), transient receptor potential vanilloid 1 (TRPV1) and
calcitonin gene-related peptide (CGRP) in the dorsal root ganglia (DRG) tissues. In-vitro studies were
performed on primary DRG neurons which were obtained from both thoracic and lumbar DRG of rats.
Results indicated that AOPPs triggered reactive oxygen species (ROS) production in DRG neurons, which
were signiﬁcantly abolished by ROS scavenger N-acetyl-L-cysteine (NAC) and small-interfering RNA
(siRNA) silencing of Nox1 or Nox4. The expressions of Nox1, Nox4, TRPV1 and CGRP were signiﬁcantly
increased in AOPPs-induced DRG neurons. And relevant siRNA or inhibitors notably suppressed the
expressions of these proteins and the calcium inﬂuxes in AOPPs-induced DRG neurons. In conclusion,
AOPPs increased signiﬁcantly in CFA-induced hyperalgesia rats and they activated Nox1/Nox4-ROS to
sensitize TRPV1-dependent Ca2þ inﬂux and CGRP release which led to inducing mechanical hyper-
algesia.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hyperalgesia is a multifactorial situation caused by injury or
dysfunction of the nervous system, this situation results in the
increasing response to noxious stimuli [1]. Because pain hy-
persensitivity can persist long after the healing of the initial da-
mage, it causes major health problems around the world [2]. In-
terestingly, many patients with systemic disorders, such as spinal
cord injury (SCI) [3] and diabetes [4], suffer from hyperalgesia.
Almost all of these patients accompany with oxidative stress when
excessive amount of reactive oxygen species (ROS) are formed orB.V. This is an open access article u
henjt99@tom.com (J. Chen).
.when the antioxidant capacity is decreased [5,6], and such im-
balance may be a key factor to hyperalgesia [7]. The increasing
knowledge about the molecular biology of ROS, such as hydrogen
peroxide (H2O2) and superoxide (O2), highlights their im-
portant role in their essential contribution to the development of
pain hypersensitivity [8]. However, the source of hyperalgesia-re-
lated ROS and the underlying mechanisms still remain unclear.
Although there are numerous potential sources of ROS, nicoti-
namide adenine dinucleotide phosphate (NADPH) oxidase, the
membrane-bound enzyme complexes, play a key role in the pro-
duction of ROS [9]. In general, 4 rodent genes of the catalytic
subunit Nox (Nox1–Nox4), which are expressed in a tissue-speciﬁc
manner, have been identiﬁed [10]. For example, Nox1 is implicated
in ROS generation in the development of thermal and mechanical
hyperalgesia [11]. Nox2 is induced in spinal cord microglia cells
after peripheral nerve injury and contributes to neuropathic painnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and plays a crucial role in balance and gravity [13]. And Nox4
contributes to pain signaling after peripheral nerve injury. Nox4
mRNA has been detected in dorsal root ganglia, and Nox4-derived
ROS production in the injured peripheral nerve stump essentially
contributed to the initiation or maintenance of pain hypersensi-
tivity [14].
Advanced oxidation protein products (AOPPs) are dityrosine-
containing and cross-linking protein products, which are formed
primarily as a consequence of oxidative stress [15]. AOPPs have
been considered as a novel marker of oxidant-mediated protein
damage. Recently, AOPPs have been recognized as a marker of
oxidative stress and as a mediator of inﬂammation involved in the
pathophysiology of many diseases [16–18]. It has been demon-
strated that AOPPs are important source of ROS in vivo [19]. Fur-
thermore, the roles of AOPPs in activating NADPH oxidase have
been well documented. AOPPs can increase Nox1, Nox2 and Nox4
expression, and these are key regulatory subunits of NADPH oxi-
dase [20].
The transient receptor potential vanilloid channel 1 (TRPV1) is
a nonselective cation channel and is abundantly distributed in
small and medium diameter primary afferent neurons of the
dorsal root ganglion (DRG) [21]. Considerable evidences indicated
that TRPV1 could be activated and potentiated by NADPH oxidase
generated ROS [22]. Activation of TRPV1 enhanced intracellular
calcium accumulation due to its permeability to Ca2þ[23], which
was involved in many reactions (such as cellular viability, apop-
tosis, and physiological signal transduction). Meanwhile, enhanced
TRPV1 caused the release of calcitonin gene-related peptide
(CGRP) from DRG neurons, which played a key role in initiating
neurogenic inﬂammation and leading to hyperalgesia [24].
Therefore, this study was conducted to examine whether
AOPPs could cause hyperalgesia and the potential mechanisms.
Herein, we ﬁrst reported AOPPs increase in complete Freund’s
adjuvant (CFA)-induced hyperalgesia rats, and we also identiﬁed a
potential role of AOPPs in activating TRPV1 via NADPH oxidase-
dependent ROS production, which also mediated CGRP upregula-
tion and calcium inﬂux increase. These data provided new in-
formation for understanding the source of hyperalgesia-related
ROS and the underlying mechanisms of AOPPs-induced
hyperalgesia.2. Materials and methods
2.1. Animals
Male Sprague-Dawley rats (initial weight 200–250 g, Animal
Experiment Center, Southern Medical University, Guangzhou,
China) were used in this study. Rats were housed 5 per cage under
a standard 12 h/12 h light/dark cycle with food and water available
ad libitum. Before any experimental procedures, rats were accli-
mated for 7 days. All experiments followed the recommendations
of the International Association of Studies on Pain, and were ap-
proved by the Laboratory Animal Care and Use Committee of
Nanfang hospital, Southern Medical University (NFYY-2014-86).
2.2. Chemicals and antibodies
The following chemicals and antibodies were obtained from
Sigma-Aldrich (St. Louis, MO, USA): Complete Freund's adjuvant
(CFA), rat serum albumin (RSA), hypochlorous acid (HOCl), ame-
bocyte lysate assay kit, chloramine-T, acetic acid, 4% paraf-
ormaldehyde, bovine serum albumin (BSA), trypsin, collagenase
type IA, DNase type IV, cytosine arabinoside, thiazolyl blue tetra-
zolium blue (MTT), dimethyl sulfoxide (DMSO), 2′,7′-dichloroﬂuorescein diacetate (DCFH-DA), phenylmethylsulfonyl
ﬂuoride (PMSF), protease and phosphatase inhibitors, Fura-2/AM,
apocynin, N-acetyl-L-cysteine (NAC), and SB366791. Dulbecco’s
modiﬁed Eagle’s medium (DMEM; 4.5 g/L glucose), fetal bovine
serum (FBS), penicillin, streptomycin and glutamine were pur-
chased from Gibco (CA, USA). Detoxi-Gel column and BCA Protein
Assay Kit were purchased from Thermo Fisher Scientiﬁc (MA,
USA).
The primary antibodies used in this study were rabbit anti-
NADPH oxidase 1, anti-NADPH oxidase 2, anti-NADPH oxidase 4,
rabbit anti-TRPV1, rabbit anti-calcitonin gene-related peptide
(CGRP) and chicken anti-beta III Tubulin antibody and rabbit anti-
β-actin from Abcam (MA, USA). Secondary antibodies conjugated
with FITC or Cy3 were purchased from Abcam (MA, USA).
2.3. Preparation of AOPPs-RSA and determination
As previously described, AOPPs-RSA were prepared with minor
modiﬁcations [25]. In brief, 20 mg/mL of RSA was added to
200 mM of HOCl for 30 min at room temperature and dialyzed for
24 h against PBS at 4 °C to remove the free HOCl. Control in-
cubation was performed in native RSA dissolved in PBS alone. All
the preparations were passed through a Detoxi-Gel column to
remove any contaminated endotoxin. Endotoxin levels were
measured with an amebocyte lysate assay kit and were found to be
below 0.025 EU/mL. To quantify AOPPs concentration [26], 200 mL
of sample or chloramine-T was placed in a 96-well plate, and then
20 mL of acetic acid was added. SpectraMax M5 Multifunctional
Microplate Reader (Molecular Devices, CA, USA) was used to
measure the absorbance at 340 nm immediately. The content of
AOPPs in the AOPPs-RSA was 58.1372.62 mmol/g protein versus
0.2270.03 mmol/g protein in unmodiﬁed RSA.
2.4. Animal experimental design
Hyperalgesia was induced by injecting subcutaneously an
emulsion of 100 μL of CFA 50% dissolved in PBS (sterilized) into the
left hind paw, while the rats were under brief isoﬂurane an-
esthesia. Sham rats received a 100 μL injection of PBS (sterilized)
[27]. For characterization of paw withdrawal threshold, CFA group
and corresponding PBS group (n¼4 rats/group) were tested 3 days
before injection and in the time course experiment at days 0, 3, 6,
9, 12, 15, 18 and 21 after CFA injection. Plasma AOPPs concentra-
tion in the CFA model was measured after deeply anesthetized
with pentobarbital sodium (150 mg/kg) at Day 21.
For AOPPs-induced hyperalgesia, the rats were randomly di-
vided into 5 groups (5 rats per group): AOPPs-RSA group, PBS
group, RSA group, apocynin group, and AOPPs-RSAþapocynin
group. In our study, we injected AOPPs-RSA into healthy SD rats,
according to plasma AOPPs concentration in the CFA model and
our previous study [17,28]. AOPPs-RSA (50 mg/kg), RSA (50 mg/
kg), and PBS (pH 7.4) were intravenously injected each day of the
study, Antioxidant apocynin (50 mg/kg) was dosed by intragastric
administration each day of the study duration. The basic threshold
of each rat was tested 3 days before drugs were injected. After
treatment, rats were tested on Days 0, 3, 6, 9,    , 27 and 30. The
time interval was 2 days. Plasma and DRG tissues were obtained
after deeply anesthetized with pentobarbital sodium (150 mg/kg)
on Day 30.
2.5. Mechanical hyperalgesia assays
This study was performed at the same time of day and by an
experimenter unaware of the treatment applied. Each rat was
placed in a clear plastic chamber on an elevated wire grid and
acclimated for at least 15 min to the testing environment prior to
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determined using an Electronic von Frey Anesthesiometer system
(IITC Life Science, CA, USA). The electronic von Frey polypropylene
tip was applied perpendicularly to the mid-plantar surface of the
selected hind paw and the intensity of the stimulus was auto-
matically recorded when the paw was ﬂexed reﬂexively followed
by a clear ﬂinch response after paw withdrawal. All rats were
tested 5 times, with an inter-test period of 15 min [29].
2.6. Immunoﬂuorescence staining
Immunoﬂuorescence staining of DRG slides was performed as
previously described [30]. Brieﬂy, rats were anesthetized with
isoﬂurane and pentobarbital sodium (150 mg/kg) at Day 30. The
lumber DRGs (L4–6) were removed and postﬁxed in 4% paraf-
ormaldehyde overnight at 4 °C and then were transferred into 30%
sucrose (in PBS) at 4 °C for at least 24 h. Samples were cryostat
sectioned at a thickness of 14–16 μm and stored at –80 °C until
use. Sections were permeabilized, blocked in 5% bovine serum
albumin in PBS for 1 h at room temperature and then incubated
overnight at 4 °C with the following antibodies: rabbit anti-Nox1
(1:500), rabbit anti-Nox2 (1:500), rabbit anti-Nox4 (1:500), rabbit
anti-TRPV1 (1:500), rabbit anti-CGRP (1:500), and chicken anti-
beta III Tubulin antibody (1:1000). After rinsing in PBS, slides were
incubated with secondary antibodies conjugated with FITC (1:500)
or Cy3 (1:200) for 2 h at room temperature. Then, reacted slides
were mounted and cover slipped. Images were captured with an
Olympus FluoView FV10i self-contained confocal laser scanning
microscope system (Olympus America Inc., PA, USA).
2.7. Primary sensory neurons culture
DRG from thoracic and lumbar spinal cord of rats were minced
in cold PBS and incubated for 60–90 min at 37 °C in DMEM (4.5 g/L
glucose) containing (in mg/mL): 0.5 trypsin, 1 collagenase type IA,
and 0.1 DNase type IV. Fetal bovine serum was added to neutralize
trypsin. Neurons were pelleted, suspended in DMEM containing
10% fetal bovine serum, 100 U/mL penicillin, 0.1 mg/mL strepto-
mycin, 2 mM glutamine. Cells were plated on polylysine-coated
wells. Cytosine arabinoside (1 μM) was added to eliminate mitotic
cells, which including Schwann cells and ﬁbroblasts. Cultures were
maintained at 37 °C in a water-saturated atmosphere with 5% CO2
for 3 d prior to start of the experiment [31].
2.8. Cell viability (MTT) assay
To determine the cell viability after AOPPs-RSA treatment, we
used the MTT viability assay [22]. DRG neurons were cultured with
AOPPs-RSA at the concentration of 50, 100, 200, or 400 μg/mL for
6 h and replaced the medium with control medium containing
MTT solution (5 mg/mL) in an amount equal to 10% of the culture
volume. After incubation for 4 h, removed cultures and dissolved
the resulting MTT formazan in DMSO. The absorbance was mea-
sured at a wavelength of 490 nm.
2.9. Small interfering RNA (siRNA) transfection
To introduce siRNA into rat DRG neurons, the cells were plated
on 6-well plates at 90% conﬂuence before transfection. Individual
siRNAs (at 5 nM), lipofectamine 3000 and Opti-MEM were mixed
and incubated at room temperature for 20 min siRNA– lipofecta-
mine 3000 complexes were added to cells for 24 h and the med-
ium was replaced by fresh serum DMEM medium after transfec-
tion. Nox1 siRNA (190372), Nox2 siRNA (189525) and Nox4 siRNA
(190243) were purchased from Thermo Fisher Scientiﬁc (MA,
USA). Experiments were performed 72 h after transfection.Knockdown of Nox1, Nox2 or Nox4 was assessed by western blots
assay [32].
2.10. Intracellular ROS measurement
The level of intracellular ROS was assessed by ﬂuorescence
microplate reader and confocal laser scanning microscope system
with the probe 2′, 7′-dichloroﬂuorescein diacetate (DCFH-DA),
which oxidizes to ﬂuorescent dichloroﬂuorescein (DCF) in the
presence of ROS, as described previously [17]. Brieﬂy, DRG neurons
were suspended in DMEM at a given concentration of 108/L. Each
sample was incubated in 10 mM DCFH-DA for 30 min in darkness.
The excitation and emission wavelengths were 488 nm and
525 nm, respectively. The resulting data were normalized using
the control values.
2.11. Western blot analysis
Samples were homogenized in ice-cold RIPA buffer with 1 mM
PMSF, protease, and phosphatase inhibitors and cleared by cen-
trifugation (12,000 rpm, 4 °C, 10 min). The protein concentration
in the supernatant was determined using the BCA Protein Assay
Kit. Equivalent amounts of extracted proteins (50 μg) were sepa-
rated by 10% or 12% SDS–polyacrylamide gel electrophoresis, then
electro-blotted onto polyvinylidene diﬂuoride membranes (Milli-
pore, MA, USA). The membranes were blocked using 5% blocking
buffer (5% BSA in Tris-buffered saline with 0.1% Tween 20) for 1 h
at room temperature. Blots were incubated overnight at 4 °C with
the following primary antibodies: rabbit anti-Nox1 (1:1000), rab-
bit anti-Nox2 (1:1000), rabbit anti-Nox4 (1:1000), rabbit anti-
TRPV1 (1:1000), and rabbit anti-CGRP (1:1000). The membrane
was washed 3 times with TBST for 10 min and followed by in-
cubation with appropriate secondary antibody for 2 h, and then
washed again 3 times with TBST. Relative levels of im-
munoreactivity were quantiﬁed using the Kodak In-vivo Imaging
System (Kodak, NY, USA). Rabbit anti-β-actin (1:2000) was used as
an internal control for the concentration of proteins loaded.
2.12. Measurement of intracellular free calcium
The DRG neurons were seeded in 96-well plates and loaded
with 4 μM Fura-2/AM in loading buffer for 45 min at 37 °C in the
dark, washed twice with the phosphate buffer, incubated for an
additional 30 min at 37 °C to complete probe de-esteriﬁcation. The
groups were exposed to the stimulations. Fluorescence was de-
tected by using a SpectraMax M5 Multifunctional Microplate
Reader. The ﬂuorescence at 505 nm was measured after excitation
at 340 nm and 380 nm, respectively [33].
2.13. Statistical analysis
Analyses were performed with SPSS 20.0 (IBM, NY, USA) and
GraphPad Prism 5 (GraphPad Software, CA, USA) software. Statis-
tical data are presented as means 7 SEM. Comparisons were
analyzed with student t-test (2 groups only) or ANOVA followed
by the Bonferroni post hoc tests analysis. A value of Po0.05 was
considered statistically signiﬁcant.3. Results
3.1. Plasma AOPPs increased in CFA-induced rats
We tested the paw withdrawal threshold and measured the
concentration of plasma AOPPs in CFA-induced rats. As shown in
Fig. 1A, the paw withdrawal threshold declined from Day 0
Fig. 1. The paw withdrawal threshold and the concentration of plasma AOPPs in CFA-induced rats. (A) Paw mechanical threshold was tested by the electronic von Frey
system after different treatment. (B) The concentration of AOPPs in plasma was detected by chloramine-T method. Data represent mean7SEM of at least three independent
experiments. n¼4 per group. *Po0.05 versus PBS group.
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level until Day 21 (6.5470.29 g). Fig. 1B indicated that the level of
plasma AOPPs in CFA-induced rats was 1.6-fold in comparison
with that in the PBS group (Po0.05). These data indicated that
AOPPs were present in CFA-induced rats..
3.2. AOPPs induced mechanical hyperalgesia in SD rats
To elucidate whether AOPPs could induce mechanical hyper-
algesia in SD rats, the electronic von Frey was used to measure the
mechanical threshold of rats. As shown in Fig. 2A, the basic lines of
paw mechanical threshold were determined by consecutive ex-
amination from 3 days before treatment. There was no signiﬁcant
difference among the 5 groups (the range was from 25.3670.59 g
to 26.6370.31 g, P40.05). Rats in these groups received different
treatments and the paw mechanical threshold of each rat was
tested every 3 days. After intravenous injection of AOPPs-RSA, the
mechanical threshold signiﬁcantly declined from Day 6
(19.4570.51 g) to Day 27 (5.9070.24 g) and remained a low level
until Day 30 (5.2270.33 g). In addition, we found that intragastric
administration of apocynin notably improved mechanical hyper-
algesia induced by AOPPs from Day 9. The weight of rats in each
group was recorded in Fig. 2B, and there was no signiﬁcant dif-
ference between each group (the range was from 225.0074.21 g
to 341.8078.46 g, P40.05). Plasma AOPPs levels were detected in
each group. Fig. 2C indicated that plasma AOPPs levels increased in
AOPPs-RSA group (363.7973.39 μmol/L) and AOPPs-
RSAþapocynin group (362.0372.27 μmol/L)..
3.3. AOPPs increased expression of Nox1, Nox4, TRPV1 and CGRP
in vivo
Immunoreactivity of anti-Nox1, anti-Nox2, anti-Nox4, anti-
TRPV1, and anti-CGRP was observed in sections of rat DRG (L4-L6)
neurons that were co-stained with the neuronal marker, β-tubulin
III. Fig. 3A and B revealed that Nox1 and Nox4 were markedly
increased in AOPPs-RSA group compared with that in PBS group,
and apocynin partly inhibited AOPPs-induced Nox1 and Nox4
expression. As shown in Fig. 3C, expression of TRPV1 increased in
AOPPs-RSA group, and apocynin also inhibited TRPV1 expression.
Meanwhile, increasing expression of CGRP was observed in AOPPs-
treated rats but not in rats of control group and the expression
level was alleviated by apocynin (Fig. 3D). To conﬁrm our results,
we used Western blot assays to measure the expression level of
Nox1, Nox4, TRPV1, and CGRP in DRG tissues (L4-L6) of AOPPs-
treated rats. Fig. 3E indicated that the level of Nox1 signiﬁcantlyincreased in AOPPs-RSA group. Meanwhile, the expression of Nox4
increased 2-fold in AOPPs-RSA group, and its inhibitor, apocynin,
reduced its expression level by almost 75%. The level of TRPV1
increased signiﬁcantly 2-fold in AOPPs-RSA group in comparison
with that in the PBS group, and intragastric administration of
apocynin efﬁciently reduced the expression of AOPPs-triggered
TRPV1 by 50%. Furthermore, CGRP increased close to 2-fold in the
AOPPs-RSA group compared with that in the PBS group, and were
down-regulated by apocynin by approximately 60%. Notably, the
expression of Nox2 which was tested by immunoﬂuorescence
staining or western blots had no signiﬁcant difference between
each group (Fig. S1)..
3.4. AOPPs up-regulated Nox1 and Nox4 expression in DRG neurons
To investigate the effect of AOPPs-RSA on NADPH oxidase ex-
pression in rat DRG neurons, the cells were stimulated with in-
creasing concentrations of AOPPs-RSA (0, 50, 100 and 200 μg/mL)
for different time (0, 15, 30, 60, 120 and 360 min). The protein
levels of Nox1, Nox2 and Nox4 were analyzed by western blot from
AOPPs-stimulated rat DRG neurons. The Nox1 and Nox4 protein
level gradually increased after AOPPs stimulation at 0–200 μg/mL
(Fig. 4A and C). AOPPs-RSA stimulation also time-dependently
induced Nox1 and Nox4 protein expression (Fig. 4D and F). As for
protein expression of Nox2 (Fig. 4B and E), the results showed no
signiﬁcant difference at indicated concentrations or time durations
as analyzed by Western blot. Next, we knocked down Nox1, Nox2
and Nox4 gene in DRG neurons, and Nox1, Nox2 or Nox4 siRNA
transfection dramatically reduced AOPPs-induced Nox1, Nox2 or
Nox4 expression in rat DRG neurons (Fig. 4G-I). These results in-
dicate that up-regulation of Nox1 and Nox4 may be critical for
AOPPs-mediated ROS production in rat DRG neurons..
3.5. AOPPs regulated DRG neurons to generate redundant ROS via
NADPH oxidase pathway
Previous studies demonstrated that DRG neurons produced
intracellular ROS under oxidative stress [34]. To determine whe-
ther AOPPs, as oxidative stress products, can cause redundant ROS
accumulation inside DRG neurons, we examined intracellular ROS
levels in AOPPs-treated DRG neurons. According to 6 h MTT test
results (Fig. 5A), 400 μg/mL AOPPs-RSA caused signiﬁcant DRG
neurons death (cell viability was 61.8074.20%), while incubation
in 0 to 200 μg/mL AOPPs-RSA had little effects on cell fatality (cell
viability was above 95%). Thus, we subjected DRG neurons cultures
to increasing concentrations of AOPPs-RSA (0, 50, 100 and
Fig. 2. AOPPs induced mechanical hyperalgesia in SD rats. (A) The basic lines of
paw mechanical thresholds were tested 3 days continuously before treatment. Paw
mechanical threshold was tested by the electronic von Frey system after different
treatments. (B) The weight of each rat was measured every 3 days. (C) The con-
centration of AOPPs in plasma was detected by chloramine-T method. Data re-
present mean 7 SEM of at least 3 independent experiments. n¼5 per group.
*Po0.05 versus PBS group. # Po0.05 versus AOPPs-RSAþapocynin group.
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ROS production was increased in DRG neurons cultured with
AOPPs-RSA in a dose- and time-dependent manner (Fig. 5B and C).
For further conﬁrmation, ROS generation in DRG neurons cultured
with control medium, RSA, AOPPs-RSA (200 mg/mL),
AOPPsþsiNox1, AOPPþsiNox2, AOPPþsiNox4, AOPPþNAC
(2 mM, 2 h) was observed under a confocal laser scanning mi-
croscope system using DCFH-DA probe (Fig. 5E)..
To elucidate the function of NADPH oxidases in ROS generation,
DRG neurons were respectively pre-treated with ROS scavenger
NAC (2 mM, 2 h), Nox1 siRNA, Nox2 siRNA or Nox4 siRNA. After
these treatments, DRG neurons were incubated with 200 μg/mLAOPPs-RSA for 120 min. The level of ROS generation was sig-
niﬁcantly decreased in DRG neurons which were pretreated with
NAC, Nox1 siRNA, or Nox4 siRNA separately (Fig. 5D), whereas
Nox2 siRNA had little impact on the elevated levels of ROS. The
results implied that AOPPs-RSA might elevate the levels of ROS in
DRG neurons by activating Nox1 or Nox4.
3.6. AOPPs promoted CGRP release in DRG neurons through Nox1/
Nox4-ROS-TRPV1
Western blot assay was used to verify the AOPPs-Nox1/Nox4-
ROS-TRPV1-CGRP pathway. We stimulated DRG neurons with
different concentrations of AOPPs-RSA (50, 100 and 200 μg/mL) for
6 h. The results showed that 50 μg/mL AOPPs-RSA could sig-
niﬁcantly activate TRPV1, and the expression level of TRPV1 was
elevated with the increasing concentration of AOPPs-RSA (Fig. 6A).
However, the expression of CGRP did not increase until the con-
centration of AOPPs-RSA reached 100 μg/mL (Fig. 6C). In addition,
DRG neurons were stimulated by 200 μg/mL AOPPs-RSA for dif-
ferent time durations (0, 15, 30, 60, 120 and 360 min). The ex-
pression of TRPV1 was up-regulated at least 3-fold at 30 min in
comparison with that at 0 min (Fig. 6B). The level of CGRP was
increased close to 1.4-fold after 60 min (Fig. 6D)..
To further elucidate this pathway, DRG neurons were pre-
treated with Nox1 siRNA, Nox4 siRNA, NAC (2 mM) or SB366791 (a
TRPV1 inhibitor, 1 μM) [35] before AOPPs-RSA (200 μg/mL, 6 h)
treatment. Our previous results indicated that Nox2 was not ac-
tivated in AOPPs-induced ROS generation, so we did not use Nox2
siRNA in the transfection experiments. We found that the ex-
pressions of TRPV1 and CGRP were signiﬁcantly decreased under
these conditions (Fig. 6E). These results indicated that Nox1 and
Nox4 participated in AOPPs-mediated TRPV1 and CGRP expression
in rat DRG neurons observed in vitro.
3.7. AOPPs induced calcium inﬂuxes through activating TRPV1
channel
ROS increase intracellular free calcium by acting speciﬁcally on
TRPV1 [22]. AOPPs -treated DRG neurons (200 μg/mL, 2 h) showed
more calcium inﬂuxes comparing to those in the control group
(Fig. 7A). We further assessed calcium ﬂuxes in DRG neurons
which were pretreated with Nox1 siRNA, Nox4 siRNA, NAC (2 mM,
2 h), or SB366791 (1 μM, 2 h) and then incubated with 200 μg/mL
AOPPs-RSA for 2 h. Fig. 7B showed that, comparing with the
control group, despite of the fact that the concentration of in-
tracellular calcium were higher in AOPPsþsiNox1 group,
AOPPsþsiNox4 group and AOPPsþNAC group, these inhibitors
could efﬁciently decrease the concentration of intracellular free
calcium which was induced by AOPPs..4. Discussion
Our study identiﬁed advanced oxidation protein products
(AOPPs), a novel marker of oxidative stress, increased in complete
Freund’s adjuvant (CFA)-induced hyperalgesia model. To our
knowledge, this is the ﬁrst evidence for a function of AOPPs in a
pathophysiological process implicating the nervous system and, in
particular, hyperalgesia pathogenesis.
In 1996, the ﬁrst report of AOPPs was made by Witko-Sarsat
after the discovery of AOPPs in the plasma of uremic patients re-
ceiving maintenance dialysis [15]. Increasing evidences suggested
that the formation and accumulation of plasma AOPPs served as
pathogenic mediators that participated in various diseases, such as
diabetes [16,36], coronary artery disease [18], cancer [37], liver
cirrhosis [38], and chronic inﬂammatory bowel disease (IBD) [17].
Fig. 3. Expression levels of Nox1, Nox4, TRPV1 channel and CGRP were detected in DRGs (L4–L6) in rats. (A–D) Immunoﬂuorescence staining of DRGs in different groups, the
target protein (Nox1, Nox4 TRPV1 and CGRP) was stained green, while β-tubulin III was red. (E) Expression levels of Nox1, Nox4, TRPV1, and CGRP in DRGs tissues (L4–L6)
were detected by Western blotting. Data represent mean 7 SEM of at least 3 independent experiments. n¼5 rats per group. scale bar, 20 mm *Po0.05 versus PBS group. #
Po0.05 versus AOPPs-RSA group.
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[27]. However, little is known about the relationship between
AOPPs and hyperalgesia. First, we detected the plasma con-
centration of AOPPs in the CFA-induced rats. Our results indicated
that plasma AOPPs increased about 1.6-fold in comparison with
that in normal rats. These results offered a reliable evidence for
our follow-up studies about intravenous injection of AOPPs.
Meanwhile, these showed that AOPPs might participate in the
hyperalgesia process, which highlights the urgent need to under-
stand whether AOPPs can induce the hyperalgesia and the un-
derlying mechanisms.
We then wondered whether AOPPs could induce mechanical
hyperalgesia. The paw mechanical threshold showed a tre-
mendous decline from Day 6 to Day 27 and remained at a low level
until Day 30 in AOPPs-induced rats. We also detected plasma
AOPPs level in rats at Day 30, and the results suggested thathyperalgesic efﬁcacy of AOPPs was due to its biological effects.
Interestingly, we found that the paw mechanical threshold of
AOPPs-induced rats accorded with that of the CFA-induced rats, in
which the plasma AOPPs concentration was 1.6 times compared
with that in the PBS group. These data further reinforced the hy-
pothesis of a potential role for AOPPs in the hyperalgesia
processes.
Next, we investigated the possible involvement of TRPV1 in
AOPPs-induced hyperalgesia processes. Previous theories estab-
lished that peripheral TRPV1 primarily mediated thermal hyper-
algesia. But recent studies have demonstrated that TRPV1 channel
in DRG neurons mediated not only thermal hyperalgesia but also
mechanical hyperalgesia [39–42]. Among TRP channels, the tran-
sient receptor potential ankyrin-1 (TRPA1) and TRPV1 are essential
and widely studied molecular sensors and mediators of pain sig-
nals in DRG neurons. It is well documented that most if not all
Fig. 4. The expression of NADPH oxidase in DRG neurons. (A, C) The levels of Nox1 and Nox4 were up-regulated signiﬁcantly in DRG neurons incubated with AOPPs-RSA in
indicated concentrations. (B) Indicated concentrations of AOPPs-RSA could not signiﬁcantly up-regulate the expression of Nox2. (D, F) The levels of Nox1 and Nox4 were up-
regulated signiﬁcantly in DRG neurons incubated with 200 μg/mL AOPPs-RSA in different time durations. (E) The expression of Nox2 had no signiﬁcant difference between
indicated time durations in 200 μg/mL AOPPs-RSA-induced DRG neurons. (G-I) After Nox1 siRNA, Nox2 siRNA or Nox4 siRNA pretreatment, cells were stimulated with or
without AOPPs-RSA (200 μg/mL) for 6 h, bar graph showed quantitative analysis of Nox1, Nox2 and Nox4. Data represent mean7SEM of at least 3 independent experiments.
*Po0.05 versus Control (0) group. # Po0.05 versus AOPPs-RSA group.
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literatures on the functional effects of oxidative stress modiﬁcation
on TRPV1 channels [22,44], but little information regarding the
role of AOPPs in the activation of TRPV1 channels. Herein, our
immunoﬂuorescence results conﬁrm that TRPV1 is up-regulated
in vivo, suggesting that AOPPs enhance TRPV1 expression resulting
in mechanical hyperalgesia. On the other hand, we explored the
involvement of TRPV1 in the regulation of this mechanism in
primary cultured DRG neurons. We found that AOPPs could in-
crease levels of TRPV1, which played a key role in the regulation of
CGRP and intracellular calcium. However, we still cannot conﬁrm
that TRPV1 channel is the only TRP family that is activated. Further
investigation is required to deﬁne the speciﬁcity.
As previously reported, emerging studies pointed the oxidative
stress, especially the production of ROS, as key up-regulated
TRPV1 mediators in a variety of pathologies [34], including painprocesses [7,8]. AOPPs can indirectly sensitize NADPH oxidase to
cause ROS overproduction in many kinds of cells [17,45–48].
Herein, we stimulated DRG neurons with AOPPs-RSA at different
concentrations and for different time durations. This study ﬁrst
demonstrated that AOPPs could trigger DRG neurons to generate
abundant ROS. In contrast to the historical view that ROS are
merely harmful, it is now clear that ROS can function as speciﬁc
regulators of intracellular signaling pathways [49].
Moreover, we also need to ﬁgure out the source of ROS. No-
tably, Nox enzymes are distinct from most other ROS sources in
that ROS generation is their major function but not a byproduct of
other biological reactions [2]. We highlighted the speciﬁc role of
Nox1, Nox2 and Nox4 in AOPPs-induced signaling. Our results
showed that in cultured primary DRG neurons, AOPPs could sig-
niﬁcantly up-regulate Nox1 and Nox4. Whereas, they had little
impact on the regulation of Nox2, which is considered
Fig. 5. AOPPs challenge increased reactive oxygen species (ROS) generation in DRG neurons via NADPH oxidase. (A) Viability of DRG neurons treated with AOPPs in different
concentrations after cultured for 6 h. (B) DRG neurons were cultured as control cells, RSA group or with indicated concentration of AOPPs-RSA as AOPPs group for 2 h.
(C) DRG neurons were incubated with 200 μg/mL AOPPs-RSA for indicated time. (D) DRG neurons were treated with AOPPs-RSA (200 μg/mL) with or without Nox1 siRNA,
Nox2 siRNA, Nox4 siRNA or NAC (2 mM, 2 h). AOPPs-induced ROS production was signiﬁcantly diminished by NAC and Nox1 siRNA, Nox4 siRNA. (E) DRG neurons were
cultured with control medium, RSA, AOPPs-RSA (200 mg/mL), AOPPsþsiNox1, AOPPsþsiNox2, AOPPsþsiNox4, AOPPsþNAC for 120 min. Confocal laser scanning microscope
system was used to visualize ROS generation in DRG neurons with the use of DCFH-DA. Data represent mean7SEM of at least 3 independent experiments. Scale bar, 20 mm.
*Po0.05 versus control (0) group. # Po0.05 versus AOPPs-RSA group.
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present ﬁndings did not support the role of Nox2 in our AOPPs-
induced molecular pathway, but they might be attributed to the
close proximity between Nox1/Nox4 and the target molecule
identiﬁed in this study, which enables direct interaction andmodulation of TRPV1 activity in DRG neurons. To best illuminate
Nox1/Nox4-ROS-TRPV1 pathway, we used a series of siRNAs and
inhibitors, such as siRNA Nox1, siRNA Nox4, NAC and SB366791.
Collectively, these data ﬁrst suggested that AOPPs might act as a
key mediator for activating Nox1 and Nox4, and were necessary in
Fig. 6. The expression of related proteins in DRG neurons. (A–D) The levels of TRPV1 and CGRP were up-regulated signiﬁcantly in DRG neurons incubated with AOPPs-RSA in
indicated concentrations and time durations. (E) DRG neurons were incubated with AOPPs-RSA (200 μg/mL) with or without pretreatment with Nox1 siRNA, Nox4 siRNA,
NAC (2 mM), or SB366791 (1 μM) for 6 h. The expression of TRPV1 and CGRP could be trigged by AOPPs, meanwhile, inhibited by these siRNAs or inhibitors. Data represent
mean7SEM of at least 3 independent experiments. *Po0.05 versus Control (0) group. # Po0.05 versus AOPPs-RSA group.
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dundant ROS, and in ﬁnal, led to activating TRPV1 channel.
In addition, we found that Ca2þ inﬂux happened via theactivation of TRPV1 channels under the condition of AOPPs
treatment. Intracellular Ca2þ pools play an important role in cel-
lular activities. Increases in Ca2þ concentration may conduce to
Fig. 7. Intracellular free calcium was detected by Fura-2/AM. (A) The levels of calcium were shown in F340/F380. (B) DRG neurons were incubated with AOPPs-RSA
(200 μg/mL) with or without Nox1 siRNA, Nox4 siRNA, NAC (2 mM, 2 h), or SB366791 (1 μM, 2 h). F340/F380 was used to indicate Intracellular free calcium. Data represent
mean7SEM of at least 3 independent experiments. *Po0.05 versus Control group. # Po0.05 versus AOPPs-RSA group.
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membrane proteins that will enhance channel potency, and acti-
vation of a variety of intracellular enzymes [52]. Previous studies
have shown that the intracellular Ca2þ inﬂux into DRG neurons
through activation of TRPV1 channels played a key role in neuro-
transmitter release and pain hypersensitivity [21]. Hence, we
provided the novel ﬁnding that AOPPs potently increased in-
tracellular calcium by Nox1/Nox4-ROS mediated TRPV1 channel
activation.
Finally, we detected immunoreactivity of CGRP in DRG tissues
of rats and in the AOPPs-treated DRG neurons, the results in-
dicated that AOPPs-induced CGRP release depended on the pre-
sence of TRPV1 channel. It has been ascertained that calcitonin
gene-related peptide (CGRP), a 37-amino-acid peptide, is wide-
spread in the neural systems [53]. CGRP is synthesized and stored
in sensory neurons and can be released from both their central and
peripheral axons [24]. Considerable evidences indicated that the
release of CGRP from sensory nerve terminals played a key role in
hyperalgesia [54,55]. It is well established that the synthesis and
release of CGRP were regulated by the activation of TRPV1 [56]. On
the other hand, Ca2þ released from intracellular stores probably
contributes to the CGRP release [57]. Although our results sug-
gested that AOPPs could sensitize TRPV1 to enhance CGRP release
and cause mechanical hyperalgesia, we cannot exclude the possi-
bility that AOPPs also sensitizes other cell types to enhance
nociception.
In summary, our study provided for the ﬁrst time that plasma
AOPPs were increased in CFA-induced hyperalgesia rats. We
identiﬁed a novel mechanism by which AOPPs sensitized TRPV1 to
induce sustained mechanical hyperalgesia. Sensitization required
activation of Nox1/Nox4 and was probably mediated by direct
generating ROS to enhance channel gating. AOPPs-induced sensi-
tization of TRPV1 caused intracellular Ca2þ increasing, enhanced
CGRP release, and exacerbated pain hypersensitivity.Conﬂict of interest
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